Mondobiotech Holding AG Company presentation

More documents

Recommendations

Info

Current Pipeline DasKloster 1000-01 Pulmonary Arterial Hypertension (PAH) ODD obtained DasKloster 1000-04 Acute Respiratory Distress Syndrome (ARDS/ALI) DasKloster 0141-01 Acute Respiratory Distress Syndrome (ARDS/ALI) DasKloster 1001-01 Idiopathic Pulmonary Fibrosis (IPF) DasKloster 0112-01 Sarcoidosis DasKloster 0210-01 Chronic Beryllium Disease DasKloster 0014-01 HBV-induced Hepatocellular Carcinoma DasKloster 0249-01 Drug-Resistant Tuberculosis ODD obtained ODD obtained ODD obtained ODD obtained ODD obtained ODD obtained In addition to the 8 Medicinal Product Candidates ready for licensing, 73 new Medicinal Product Candidates are in development 42
Scientific Snapshot Information: DK-1000-01 §� Pulmonary Arterial Hypertension (PAH) is a debilitating and often fatal disease which affects the small pulmonary arteries. PAH is characterised by a de-regulated biology of cells in the lung leading to a narrowing of the blood vessels (vasoconstriction), vascular smooth muscle cell proliferation, remodeling, and perivascular inflammation. As a consequence of this high resistance, an abnormally high blood pressure is built up in the lungs placing a strain on the right side of the heart, eventually leading to progressive right heart failure with a fatal outcome after a period of severe debilitation. • Panel A shows a normal heart • Panel B pulmonary hypertension. • RV, right ventricle; LV, left ventricle; • RA right atrium; LA, left atrium • Mechanism of Action: DK-1000 is a synthetically-produced peptide which acts via specific G protein-coupled receptors which are present in the lungs and peripheral tissues. These receptors are present on thymocytes, T cells, macrophages, monocytes, endothelial cells and vascular smooth muscle cells. DK-1000 is a potent vasodilator which also has inhibitory effects on smooth muscle cell proliferation, inflammation and platelet aggregation. DK-1000 has potential to provide therapeutic benefit to PAH patients by lowering pulmonary arterial pressure, increasing cardiac output, and reducing inflammation. Despite the broad range of drugs which are used to treat PAH (usually in combinations) DK-1000 has the potential to provide the combined pharmacological effects of a vasodilator and an anti-inflammatory in a monotherapy. §� Key data (Clinical PoC data): In clinical PoC, inhaled DK-1000 improves hemodynamic and prognostic parameters of PAH and leads to an increase in the distance achieved during a 6-minute walk test. 43
Page 1 and 2: Mondobiotech Holding AG Company pre
Page 3 and 4: mondoBIOTECH at a glance • Headqu
Page 5 and 6: Board of Directors Robert Edward Pa
Page 7 and 8: Our approach to drug discovery •
Page 9 and 10: Introduction to the Search&Match me
Page 11 and 12: The Model • Knowledge from litera
Page 13 and 14: The Search and Match Software Platf
Page 15 and 16: Match • Any path through the know
Page 17 and 18: Match - a multi-technique approach
Page 19 and 20: Bio-Mathematical Technology Platfor
Page 21 and 22: Match - Project DK-0112-01 21
Page 23 and 24: Match - Project DK-1001-01 23
Page 25 and 26: MPC Validation: the mondoBIOTECH Co
Page 27 and 28: Set up of new projects PROJECT SET
Page 29 and 30: Intellectual Property Strategy & Cu
Page 31 and 32: mondoBIOTECH’s IP Strategy Two in
Page 33 and 34: mondoBIOTECH’s IP Strategy: Two I
Page 35 and 36: Orphan Drug Designations 10 Granted
Page 37 and 38: Why Peptides Peptides characteristi
Page 40 and 41: Diversifying the Risk in Drug Disco
Page 46: Scientific Snapshot Information: DK
Page 49 and 50: Scientific Snapshot Information: DK
Page 51 and 52: Products licensed DasKloster 1001-0
Page 53 and 54: Licensed Products • Aviptadil pla
Page 55: mondoBIOTECH holding AG DasKloster

Mondobiotech Holding AG Company presentation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?